A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults.

MLA

Gunale, Bhagwat, et al. “A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Tetravalent Live Attenuated Dengue Vaccine in Adults.” Vaccine, vol. 41, no. 38, Aug. 2023, pp. 5614–21. EBSCOhost, https://doi.org/10.1016/j.vaccine.2023.07.045.

APA

Gunale, B., Farinola, N., Yeolekar, L., Shrivastava, S., Girgis, H., Poonawalla, C. S., Dhere, R. M., Arankalle, V., Chandra Mishra, A., Mehla, R., & Kulkarni, P. S. (2023). A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults. Vaccine, 41(38), 5614–5621. https://doi.org/10.1016/j.vaccine.2023.07.045

Chicago

Gunale, Bhagwat, Nicholas Farinola, Leena Yeolekar, Shubham Shrivastava, Hanna Girgis, Cyrus S Poonawalla, Rajeev M Dhere, et al. 2023. “A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Tetravalent Live Attenuated Dengue Vaccine in Adults.” Vaccine 41 (38): 5614–21. doi:10.1016/j.vaccine.2023.07.045.